Mineralys Therapeutics, Inc. (MLYS) Insider Ownership

According to recent filings covering the 90 days ending February 10, 2026, the three most significant insider holders at Mineralys Therapeutics are Director Brian Taylor Slingsby (7.90Mn shares), TenPercentOwner Biocapital Gp, Llc Samsara (5.67Mn shares), Director Capital Management, L.P. Ra (5.46Mn shares).

• A detailed ownership breakdown for Mineralys Therapeutics is not available at this time.
• Insider stakeholders control 35.06% of Mineralys Therapeutics's total share count as of February 10, 2026, holding approximately 24.90Mn shares against 71.02Mn outstanding shares.
• During the 90-day period through February 10, 2026, Mineralys Therapeutics experienced a 13.92% decreased in insider ownership, with total insider shares declining from 28.93Mn to 24.90Mn.
• As of February 10, 2026, Chief Medical Officer David Malcom Rodman recorded the highest insider purchase activity at Mineralys Therapeutics, accumulating 269.36K shares during the past 90 days.
• As of February 10, 2026, Director Brian Taylor Slingsby executed the most significant insider divestiture at Mineralys Therapeutics, disposing of 1.00Mn shares over the last 90-day period.